Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-06
2006-06-06
Schultz, James (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000, C536S023100, C536S024500
Reexamination Certificate
active
07056896
ABSTRACT:
Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds are oligonucleotides which contain at least one region of 2′-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5212295 (1993-05-01), Cook
patent: 5220007 (1993-06-01), Pederson et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5457189 (1995-10-01), Crooke et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5523389 (1996-06-01), Ecker et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5591600 (1997-01-01), Ecker
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5599797 (1997-02-01), Cook et al.
patent: 5607923 (1997-03-01), Cook et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5658891 (1997-08-01), Draper et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5681747 (1997-10-01), Boggs et al.
patent: 5681944 (1997-10-01), Crooke et al.
patent: 5691461 (1997-11-01), Ecker et al.
patent: 5877309 (1999-03-01), McKay et al.
patent: 5955443 (1999-09-01), Bennett et al.
patent: 5985558 (1999-11-01), Dean et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6127533 (2000-10-01), Cook et al.
patent: 6166197 (2000-12-01), Cook et al.
patent: 6172209 (2001-01-01), Manoharan et al.
patent: 6271358 (2001-08-01), Manoharan et al.
patent: 6277967 (2001-08-01), Manoharan
patent: 6300491 (2001-10-01), Bennett et al.
patent: 6326358 (2001-12-01), Manoharan
patent: WO 93/07883 (1993-04-01), None
patent: WO 93/18052 (1993-09-01), None
patent: WO 94/08003 (1994-04-01), None
patent: WO 95/13834 (1995-05-01), None
Branch, A. D., (1998).Trends Biochem Sci. Feb. 1998;23(2):45-50.
Gewirtz et al., Proc. Natl. Acad. Sci. v 93, pp. 3161-3163.
Agrawal, S. Trends Biotechnol. Oct. 1996;14(10):376-87.
Braasch, D. A. Biochemistry. Apr. 2002; 41(14): 4503-4510.
Tamm, I. et al. The Lancet. Aug. 2001, 358: 489-497.
Opalinska and Gewirtz, Nature Reviews 2002. 1:503-514.
Albert, P.R. et al., “Antisense knockouts: molecular scalpels for the dissection of signal transduction”,Trends Pharmacol. Sci.,1994, 15, 250-254.
Baker, B.F. et al., “2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells”,J. Biol. Chem.,1997, 272, 11994-12000.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 15th Edition, Rahway, N.J., 1987, 2301-2310.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 15th Edition, Rahway, N.J., 1987, 2263-2277.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 15th Edition, Rahway, N.J., 1987, 2283-2287.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 15th Edition, Rahway, N.J., 1987, 2286-2292.
Bernhard et al., “Direct Evidence Linking Expression of Matrix Metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells,”Proc. Natl. Acad. Sci. U.S.A.,1994, 91, 4293-4297.
Birkedal-Hansen, “Proteolytic Remodeling of Extracellular Matrix,”Curr. Op. Cell Biol.,1995, 7, 728-735.
Boggemeyer et al., “Borrelia Burgdorferi Upregulates the Adhesion Molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro,”Cell Adhes. Commun.,1994, 2, 145-157.
Cook, P.D., “Medicinal chemistry of antisense oligonucleotides—future opportunities”,Anti-Cancer Drug Design, 1991, 6, 585-607.
Crooke, S.T. et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice”,J. Pharmacol. Exp. Therapeutics, 1996, 277, 923-937.
Crooke, S.T. et al., “Progress in Antisense Oligonucleotide Therapeutic”,Ann. Rev. Pharmacol. Toxicol.,1996, 36, 107-129.
Dean, N.M. et al., “Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorthioate antisense oligodeoxynucleotides”,Proc. Natl. Acad. Sci.,1994, 91, 11762-11766.
DeLisser et al., “Molecular and Functional Aspects of PECAM-1/CD31,”Immunol. Today, 1994, 15, 490-494.
Downward,“The ras Superfamily of Small GTP-binding proteins,”TIBS, 15, 1990, 469-472.
Englisch, U. et al., “Chemically Modified Oligonucleotides as Probes and Inhibitors”,Angew. Chem. Int. Ed. Eng.,1991, 30, 613-629.
Griffiths, C.E.M. et al., “Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Preceedes Derman T Lymphocyte Infiltration in Allergic Contact Dermatitis (Rhus dermatitis)”,Am. J. Pathology., 1989, 135, 1045-1053.
Gum et al.,“Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences,”J. Biol. Chem.,1996, 271, 10672-10680.
Hakugawa et al., “The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil Infilration in Cutaneous Late Phase Response in Balb/c Mice Sensitized with Ovalbumin (OVA),”J. Dermatol.,1997, 24, 73-79.
Hegemann, L. et al., “Biochemical Pharmacology of Protein Kinase C and its Relevance for Dermatology”,Pharmacology of the Skin, Mukhtar, H. (ed.), CRC Press, Boca Raton, 1992, Ch.22, 357-268.
Himelstein et al., “Proteases and Their Inhibitors in Invasion and Metastasis, Metalloproteinases in Tumor Progression: The Contribution of MMP-9,”Invasion Metastasis, 1994-95, 14, 246-258.
Ho, V.C. et al., “Treatment of severe lichen planus with cyclosporine”,J. Am. Acad. Dermatol.,1990, 22, 64-68.
Hua et al., “Inhibition of Matrix Metalloproteinase 9 Expression by a Ribozyme Blocks Metastasis in a Rat Sarcoma Model System,”Cancer Res.,1996, 56, 5279-5284.
Hurtenbach et al., “Prednisolone Reduces Experimental Arthritis and Inflammatory Tissue Destruction in Scid Mice Infected with Borrelia Burgdorferi,”Int. J. Immunopharmac, 1996, 18, 281-288.
Kabanov, A.V., “A new class of antivirals: antisense olgonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells”,FEBS Letts.,1990, 259, 327-330.
Katocs, A.S. et al., “Biological Testing”,Remington's Pharmaceutical Sciences, 18th Ed., Gennaro (ed.), Mack Publishing Co., Easton, PA, 1990, Ch. 27, 484-494.
Kerr et al., “TGF-B1 Inhibition of Transin/Stromelysin Gene Expression Is Mediated Through a Fos Binding Sequence,”Cell, 1990, 61, 267-278.
Kerr et al., “Growth Factors Regulate Transin Gene Expression by c-fos-Dependent and c-fos-Independent Pathways,”Science, 1988, 242, 1424-1427.
Kroschwitz, J.I., “Polynucleotides”,Concise Encyclopedia of Polymer Science and Engineering, 1990, John Wiley & Sons, New York, 858-859.
Letsinger, R.L. et al., “Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture”,Proc. Natl. Acad. Sci.,1989, 86, 6553-6556.
Lisby, S. et al., “Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation”,Br. J. Dermatol.,1989, 120, 479-484.
Litwin et al., “Novel Cytokine-independent Indu
ISIS Pharmaceuticals Inc.
Schultz James
Woodcock & Washburn LLP
LandOfFree
Carbohydrate or 2′-modified oligonucleotides having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbohydrate or 2′-modified oligonucleotides having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbohydrate or 2′-modified oligonucleotides having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677130